90-90-90 and ending AIDS: necessary and feasible

More than three decades into the global HIV pandemic, there are still 2·1 million new infections each year and 36·7 million people are living with HIV. By mid-2016, 18·2 million people were on antiretroviral treatment—about 50% of people living with HIV. Yet in 2015, 15 million people living with HIV were estimated to be unaware of their status and 1·1 million died of AIDS-related complications, despite the fact that US$19 billion was invested in HIV in low-income and middle-income countries.

Although its history is complex, the HIV pandemic can be characterised by three phases: devastation; discovery and action; and ending AIDS (figure). The initial response was defined by overwhelming devastation of marginalised individuals and their communities, the root causes of which were widespread denial, ignorance, stigma, fear, and neglect. It was a time when affected communities and beleaguered health-care providers struggled in isolation to minister to the sick and dying while governments, experts, and other authorities exercised little if any political will to address a burgeoning health crisis or exacerbated the crisis through their policies. Out of this suffering emerged a determined community response that demanded leadership and resources from governments. The discovery and action phase resulted from the growing community, scientific, and political response that unravelled the secrets of HIV. Despite remarkable progress, the accepted wisdom was that ending AIDS was not feasible without a vaccine or cure. Without effective treatment, the focus was on prophylaxis and treatment of opportunistic illnesses, palliative care, ensuring human rights, tackling stigma and discrimination, community support for people with HIV, and prevention methods.

The development of life-saving, triple drug therapy gave hope along with the realisation that most of the people infected with HIV lived in low-income countries. Political will to address a burgeoning health crisis, experts, and other authorities exercised little if any. The discovery and action phase resulted from the growing community, scientific, and political response that unravelled the secrets of HIV. Despite remarkable progress, the accepted wisdom was that ending AIDS was not feasible without a vaccine or cure. Without effective treatment, the focus was on prophylaxis and treatment of opportunistic illnesses, palliative care, ensuring human rights, tackling stigma and discrimination, and prevention methods. The development of life-saving, triple drug therapy in 1996 gave hope along with the realisation that most of the people infected with HIV lived in low-income countries.
Comment

countries and it was morally unacceptable to deny them treatment.\(^5\) The creation of the Global Fund to Fight AIDS, Tuberculosis and Malaria in 2001 and the US President’s Emergency Plan for AIDS Relief (PEPFAR) in 2003, the Millennium Development Goals, and the launch of WHO’s 3 by 5 initiative, signalled the translation of discovery to action. In the face of considerable scepticism, antiretroviral treatment was delivered at scale and it was subsequently shown that ART leads to a near normal disease-free lifespan and virtually eliminates the risk of HIV transmission.\(^1\)

By 2006, the old “test and wait” strategy of withholding antiretroviral treatment until people’s immune systems were severely compromised no longer made sense.\(^9\) These and other developments provided the foundation for the next phase of the HIV pandemic—ending AIDS.

This phase reflects the political shift from a struggle to contain the epidemic to the right to universal HIV treatment as part of a winnable public health battle—a goal embodied in Sustainable Development Goal 3 (table). Ending AIDS means providing treatment for at least 35 million people living with HIV for the rest of their lives or until a cure is developed. Elimination is measured as incidence of less than one case per 1000 population per year.\(^2\) HIV eradication (zero global incidence) is not feasible without deploying a cure or vaccine alongside treatment. Other prevention interventions—eg, behavioural change, pre-exposure prophylaxis, condoms, voluntary male circumcision, opioid substitution therapy, and needle and syringe programmes—will be necessary, but not sufficient on their own without universal treatment, to end AIDS in most settings.

UNAIDS, PEPFAR, national governments, and many cities have adopted the 90-90-90 target by 2020. This target calls for 90% of people living with HIV diagnosed, 90% of people diagnosed on sustained antiretroviral treatment, and, of those, 90% virally suppressed by 2020.\(^12\) The 90-90-90 and the subsequent 95-95-95 by 2030 targets translate into 73% and 86% of people living with HIV being virally suppressed on antiretroviral treatment, respectively.\(^12\) In late 2015, after the example of the USA (2012), France (2013), Brazil (2013), and seven other countries, WHO recommended starting antiretroviral treatment irrespective of CD4 cell count.\(^13\) As of July, 2017, 51 countries (73% of global HIV burden) have published test and treat guidelines.\(^13\)

As part of the 90-90-90 efforts, the Fast-Track Cities Initiative is a partnership between the City of Paris, International Association of Providers of AIDS Care (IAPAC), UNAIDS, and the UN Human Settlements Programme, in collaboration with other stakeholders, and includes more than 75 cities focused on achieving the 90-90-90 target and zero stigma through the acceleration of local AIDS responses.\(^14\) Reaching the end of AIDS, as defined by low levels of HIV incidence and AIDS-related mortality, has already been achieved in some settings. However, to end AIDS globally will require continued effort and a near doubling of the number of people on treatment.

There remains controversy about the feasibility, cost, and epidemiological impact of the 90-90-90 target, with calls for increased prioritisation of other HIV prevention methods\(^5\) and other appeals for a 30% increase in annual funding to end AIDS as a public health threat by 2030.\(^4\) Using a conservative $300 per person for antiretroviral treatment would result in an $11 billion annual price tag for 36.7 million people living with HIV—far below the

---

**Table: End of AIDS, HIV control, elimination, eradication, and extinction**

<table>
<thead>
<tr>
<th>End of AIDS (political)</th>
<th>Definition</th>
<th>Examples</th>
</tr>
</thead>
<tbody>
<tr>
<td>End of AIDS (epidemiological)</td>
<td>Reduction of HIV incidence and AIDS to below one AIDS case per 1000 population(^2)</td>
<td>Leadership in Cambodia, New York state, San Francisco, and Vancouver focuses on HIV control, ending AIDS, and getting to zero new infections</td>
</tr>
<tr>
<td>HIV control</td>
<td>The reduction of HIV disease incidence, prevalence, morbidity, or mortality to a locally acceptable level as the result of deliberate public health efforts; continued interventions will be needed to maintain the reduction and move towards elimination targets</td>
<td>San Francisco, Vancouver</td>
</tr>
<tr>
<td>HIV elimination</td>
<td>Reduction of HIV and AIDS in a defined geographical area to below one AIDS case per 1000 people living with HIV per year and a reduction of HIV incidence to one new case per 1000 population(^2)</td>
<td>Cambodia</td>
</tr>
<tr>
<td>HIV eradication</td>
<td>Permanent reduction to zero of the worldwide incidence of HIV as a result of deliberate efforts</td>
<td>None</td>
</tr>
<tr>
<td>HIV extinction</td>
<td>The specific agent no longer exists in the laboratory or nature; interventions are no longer needed</td>
<td>None</td>
</tr>
</tbody>
</table>

---

\(^3\) The 90-90-90 and 95-95-95 targets are milestones on the way to the end of AIDS as they translate into 73% and 86% of people being on treatment and virally suppressed, respectively.\(^3\)

\(^4\) The Global Plan calls for the elimination of mother-to-child transmission of HIV to less than 5% transmission.

\(^5\) The Global Plan calls for the elimination of mother-to-child transmission of HIV to less than 5% transmission.

\(^6\) Continued intervention measures are required to maintain elimination.

\(^7\) Continued intervention measures are required to maintain elimination.

\(^8\) The 90-90-90 and 95-95-95 targets are milestones on the way to the end of AIDS as they translate into 73% and 86% of people being on treatment and virally suppressed, respectively.\(^3\)

\(^9\) The 90-90-90 and 95-95-95 targets are milestones on the way to the end of AIDS as they translate into 73% and 86% of people being on treatment and virally suppressed, respectively.\(^3\)

\(^10\) The 90-90-90 and 95-95-95 targets are milestones on the way to the end of AIDS as they translate into 73% and 86% of people being on treatment and virally suppressed, respectively.\(^3\)

\(^11\) The 90-90-90 and 95-95-95 targets are milestones on the way to the end of AIDS as they translate into 73% and 86% of people being on treatment and virally suppressed, respectively.\(^3\)

\(^12\) The 90-90-90 and 95-95-95 targets are milestones on the way to the end of AIDS as they translate into 73% and 86% of people being on treatment and virally suppressed, respectively.\(^3\)

\(^13\) The 90-90-90 and 95-95-95 targets are milestones on the way to the end of AIDS as they translate into 73% and 86% of people being on treatment and virally suppressed, respectively.\(^3\)

\(^14\) The 90-90-90 and 95-95-95 targets are milestones on the way to the end of AIDS as they translate into 73% and 86% of people being on treatment and virally suppressed, respectively.\(^3\)

\(^15\) The 90-90-90 and 95-95-95 targets are milestones on the way to the end of AIDS as they translate into 73% and 86% of people being on treatment and virally suppressed, respectively.\(^3\)

\(^16\) The 90-90-90 and 95-95-95 targets are milestones on the way to the end of AIDS as they translate into 73% and 86% of people being on treatment and virally suppressed, respectively.\(^3\)
José M Zuniga
*Reuben Granich, Brian Williams, Julio Montaner, of ending AIDS. 1

is time to double down on investment and finish the job. 2

there are signs of cynicism and complacency, now is not

information technology, and enabling meaningful

efficiently using limited resources, harnessing new

through community-based comprehensive HIV services,

access to HIV self-testing, delivering life-long treatment

community engagement.

and more open data and transparency for improved

changing the way we do public health by providing

monitoring and evaluation software are already

Fourth, the information technology revolution,

value of destigmatising both HIV and HIV services.

90-90-90 target and beyond with the potential added

acting injectable antiretroviral treatment might be able

further accelerate this trend. 3

Third, comprehensive integrated community HIV service delivery models for HIV and other health services will help reach the 90-90-90 target and beyond with the potential added value of destigmatising both HIV and HIV services. Fourth, the information technology revolution, mobile computing, crowd-sourcing, and cloud-based monitoring and evaluation software are already changing the way we do public health by providing near real-time information on programme progress, and more open data and transparency for improved community engagement.

Global public health security and human rights demand a focus on ending AIDS. Prioritising expanded access to HIV self-testing, delivering life-long treatment through community-based comprehensive HIV services, efficiently using limited resources, harnessing new information technology, and enabling meaningful community engagement will all be necessary. Although there are signs of cynicism and complacency, now is not the time to falter on the collective global HIV response. It is time to double down on investment and finish the job of ending AIDS.

*Reuben Granich, Brian Williams, Julio Montaner, José M Zuniga

International Association of Providers of AIDS Care, Washington DC 20036, USA (RG, JMZ); South African Centre for Epidemiological Modelling and Analysis, Stellenbosch University, South Africa (BW); and British Columbia Centre for Excellence in HIV/AIDS, BC, Canada (JM)

rgranich@iapac.org

RG, BW, and JMZ declare no competing interests. JM has received research grants paid to his institution from the Public Health Agency of Canada, BC Ministry of Health, Canadian Institutes of Health Research/Genome BC, the US National Institutes of Health, Johnson & Johnson, and Merck Canada, and has served on the Teva Scientific advisory board participant in 2015, providing feedback as an expert in HIV.


4 Shils R. And the band played on: politics, people and the AIDS epidemic. New York: St Martin’s Press, 1987


